A bioluminescence method for screening urine cultures to provide rapid reporting of negative specimens and to select appropriate urine cultures for direct application of automated identification methods was evaluated.
Urine specimens represent a major portion of the workload and cost of running a clinical microbiology laboratory. Several attempts at reducing the effort and cost involved have been made in the past, including the use of dipstick analysis (1, 5) , Gram stains (1, 4), filter techniques (2) , and automated instruments (1, 3, 4) .
Recently published evaluations of the rapid detection of bacteriuria by bioluminescence have demonstrated this method as being both sufficiently accurate and simple to use although of questionable cost effectiveness (3, 8, 9) . This report describes our evaluation of the Lumac bioluminescence method for screening urine specimens to determine not only its accuracy and reproducibility but whether it is time and cost effective as well. Results obtained by this method were compared with those obtained by the standard urine culture procedure.
( (3, 8, 9) .
Urine specimens. A total of 2,000 urine specimens were collected over several months, and 47% of the specimens were obtained from patients seen in outpatient clinics. Only specimens that could be processed during the day shift and within 6 h of collection were used. If not processed immediately, the specimens were refrigerated before analysis.
Because requisition slips were not always available, 58 catheter specimens (2.9% of the total) were also included for analysis.
Quantitative urine culture. All urine specimens were inoculated onto a biplate of eosin-methylene blue-5% sheep blood agar with a 0.001-ml calibrated loop. Colony counts were performed after ovçrnight incubation, and the bacteria were identified when appropriate by standard methods (3), including the Micro-ID system (General Diagnostics, Div. Warner-Lambert Co., Morris Plains, N.J.). Positive cultures were defined as those containing .50,000 CFU of one or two organisms per ml.
RESULTS
A total of 841 urine specimens were positive by the bioluminescence method, and 291 were culture positive. There were 273 true-positive results (positive by both methods), 568 false-positive results (positive by the Lumac test only), 1,141 true-negative results (negative by both methods), and 18 false-negative results (negative by the Lumac test, positive by culture). Of the false-positive results, 66.9% grew on culture as mixed flora.
The sensitivity of the method, or the percentage of culture-positive specimens detected, was 93.8%, whereas the specificity, or the percentage of culture-negative specimens which had less than 200 relative light units, was 66.8%. The predictive value of a positive result was 32.5%, whereas that of a negative result was 98.4%. Table 1 shows the organisms which grew as single isolates in numbers of-104 CFU/ml. Single isolates obtained with counts of .50 x 104 CFU/ml and their respective Lumac results for both the true-positive and false-negative urine specimens are shown in Table 2 .
In an attempt to evaluate the precision of the Lumac method, we processed three samples each of 20 separate urine specimens over a short period without specifically evaluating changes in these specimens as a result of time delay (Fig. 1) . Results obtained for these three runs were generally quite similar. Indeed, there was only one instance (patient no. 14) in which a single specimen yielded both a positive and a negative Lumac result. 30,000 20,000 10,000 9,000 8,000 7,000
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5,000 4,000 3,000 2,000 1,000 900 800 700 600 500 400 300 aerogenes (50%). Other investigators (3, 8, 9) have noted similar false-negative results in their evaluations. In our hands the Lumac system appeared to be not only a sensitive method but also a reproducible one (Fig. 1 ) in meeting its objectives as a screening device for eliminating negative urine specimens from being cultured. However, a major consideration is related to cost. As already noted by other workers (3, 8, 9) , comparisons are difficult to interpret between laboratories because of the many variables unique to each work environment. Based on a volume of 2,500 urine cultures per month in our laboratory, the cost of a single biplate is $0.41, whereas that of the Lumac reagent is $1.28. These costs for both methods represent reagent costs only and do not include the costs of quality control, troubleshooting, and reagent waste. This represents a difference of $0.87 per specimen or an additional cost of $1,261.50 per month.
What cannot be calculated at this time are the overall costs incurred by the patient as a result of unnecessary antibiotic therapy and increased hospital stay, both of which could be reduced by the physician if he or she had earlier access to the results of a negative culture. Although the times required for processing and evaluating negative specimens by Lumac and by quantitative culture are essentially the same, the elapsed time from specimen arrival in the laboratory to final results is only 30 to 45 min for the Lumac system and 12 to 24 h for culture. With considerable physician education and administrative support, it should be possible to effect potential overall savings as a result of the earlier reporting time.
Costs incurred for positive specimens are a little harder to calculate. Obviously, it would be in the interest of the patient to have bacterial identification and sensitivity data reported on the same day a urine specimen is obtained. This could be done by processing specimens reported positive by the Lumac system with one of the rapid identification and sensitivity methods. However, this approach would markedly increase costs for the laboratory because of the percentage of false-positive results (28%) obtained with the Lumac system and of those specimens (3%) yielding two significant organisms. Based on the previously mentioned figure of 2,500 urine specimens and the AutoMicrobic system (Vitek Systems, Inc., Hazelwood, Mo.) for identification and antimicrobial susceptibility testing, this would represent approximately 775 cultures per month at a cost of $2.55 per AMS ID card or sensitivity card or a total cost of $3,952.50 per month. If one performed Gram stains on specimens that were positive by the Lumac system, one could eliminate approximately two-thirds of these as mixed cultures, leaving for processing only those with no organisms seen or harboring two organisms with the same Gram stain morphology. Decreased costs also could be realized by reducing the number of false-positive results due to contaminated specimens by educating those responsible to use proper collection methods for all urine specimens.
In conclusion, the Lumac detection system appears to be a rapid and sensitive screening method for eliminating a significant number (.50%) of urine specimens for culture. It is, however, a relatively expensive test whose costs would have to be justified by increased medical utility.
